Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corpor...(Condensed Consolidated Statements of Ope...)

Date:11/3/2009

Condensed Consolidated Statements of Operations (In thousands, except per share data) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, --------------- ------------------- 2009 2008 2009 2008 ---- ---- ---- ---- Operating expenses: Research and development 5,396 9,024 19,153 24,511 General and administrative 3,802 3,383 10,321 11,289 Restructuring & asset impairment - - 1,056 - ----- ------ ------ ------ Total operating expenses 9,198 12,407 30,530 35,800 ----- ------ ------ ------ Loss from operations (9,198) (12,407) (30,530) (35,800) ------ ------- ------- ------- Other income (expense), net (679) 170 (2,017) 1,177 ---- --- ------ ----- Net loss (9,877) (12,237) (32,547) (34,623) Preferred stock dividends (125) (125) (375) (375) ---- ---- ---- ---- Loss applicable to common shares $(10,002) $(12,362) $(32,922) $(34,998) ======== ======== ======== ======== Loss per share: Basic and diluted $(0.29) $(0.36) $(0.95) $(1.01) ====== ====== ====== ====== Shares used in calculation of loss per share: Basic and di
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Poniard Pharmaceuticals to Present at the 2009 UBS Global Life Sciences Conference
2. Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial Evaluating Picoplatin in Small Cell Lung Cancer Reaches 320th Event Target
3. Poniard Pharmaceuticals To Present at Three Upcoming Investor Conferences in September
4. Poniard Pharmaceuticals Reports Second Quarter 2009 Financial Results and Provides a Corporate Update
5. Poniard Pharmaceuticals to Host Second Quarter 2009 Financial Results Conference Call on August 4
6. Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors
7. Poniard Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
8. Poniard Pharmaceuticals Files Shelf Registration
9. Poniard Pharmaceuticals to Present at the Leerink Swann Oncology Roundtable Conference
10. Poniard Pharmaceuticals to Present at the 2009 BIO International Convention
11. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer